Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Status:
Recruiting
Trial end date:
2025-01-21
Target enrollment:
Participant gender:
Summary
This phase I/Ib trial seeks to find out the best dose, possible benefits and/or side effects
of cabozantinib in combination with enfortumab vedotin in treating urothelial cancer that has
spread to nearby tissues and lymph nodes (locally advanced) or other parts of the body
(metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to a
toxic agent called vedotin. Enfortumab attaches to nectin-4 tumor cells in a targeted way and
delivers vedotin to kill them. Cabozantinib in combination with enfortumab vedotin may be
safe and effective in treating locally advanced or metastatic urothelial cancer.